FDA’s budget in limbo
This article was originally published in The Rose Sheet
Executive Summary
The 109th Congress failed to pass appropriations for FDA for FY 2007, instead settling on a continuing resolution that expires Feb. 15. Incoming Democratic Appropriations Committee Chairmen Sen. Robert Byrd (W.Va.) and Rep. Dave Obey (Wisc.) plan to scrap the current Republican appropriations bills in favor of a year-long continuing resolution. The move would effectively freeze the agency's spending at FY 2006 levels until FY 2008 begins. FDA responded by stating that "a full-year continuing resolution presents difficult challenges." The agency added that between now and Feb. 15, it "will be working with the administration to analyze the impacts of a continuing resolution"...
You may also be interested in...
CFSAN Restricts Cosmetics Inspections To Limited Basis If Budget Refused
FDA will eliminate routine cosmetics inspections in fiscal year 2008 and only perform them on a "for cause" basis if the agency is forced to operate at 2006 levels under a continuing resolution, according to FDA's Feb. 5 request
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.